JP2024523839A - 突然変異体brafを分解する療法薬 - Google Patents

突然変異体brafを分解する療法薬 Download PDF

Info

Publication number
JP2024523839A
JP2024523839A JP2023575817A JP2023575817A JP2024523839A JP 2024523839 A JP2024523839 A JP 2024523839A JP 2023575817 A JP2023575817 A JP 2023575817A JP 2023575817 A JP2023575817 A JP 2023575817A JP 2024523839 A JP2024523839 A JP 2024523839A
Authority
JP
Japan
Prior art keywords
compound
amino
azaspiro
cyano
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023575817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024523839A5 (cg-RX-API-DMAC7.html
Inventor
クリストファー ジー. ナスヴェシュク
カトリーナ エル. ジャクソン
ヤンケ リャン
ロバート ティー. ユー
マルティン デュプレシ
マーク イー. フィッツジェラルド
ビクトリア ガルザ
アンドリュー チャールズ グッド
モーガン ヴェルツェル オーシェア
ゲシーネ ケルスティン ヴェイツ
コシモ ドレンテ
デイヴィッド スティーヴン ヒューウィングス
ダニエル フンツィカー
ダニエラ クルメナッハ
ピエールジョルジョ フランチェスコ トンマーゾ ペッタッツォーニ
ユルゲン ヴィヒマン
Original Assignee
シーフォー セラピューティクス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーフォー セラピューティクス, インコーポレイテッド filed Critical シーフォー セラピューティクス, インコーポレイテッド
Publication of JP2024523839A publication Critical patent/JP2024523839A/ja
Publication of JP2024523839A5 publication Critical patent/JP2024523839A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Mushroom Cultivation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023575817A 2021-06-08 2022-06-08 突然変異体brafを分解する療法薬 Pending JP2024523839A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP21178150.5 2021-06-08
EP21178145.5 2021-06-08
EP21178145 2021-06-08
EP21178152.1 2021-06-08
EP21178152 2021-06-08
EP21178150 2021-06-08
US202163277973P 2021-11-10 2021-11-10
US63/277,973 2021-11-10
PCT/US2022/032729 WO2022261250A1 (en) 2021-06-08 2022-06-08 Therapeutics for the degradation of mutant braf

Publications (2)

Publication Number Publication Date
JP2024523839A true JP2024523839A (ja) 2024-07-02
JP2024523839A5 JP2024523839A5 (cg-RX-API-DMAC7.html) 2025-06-12

Family

ID=84425525

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023575817A Pending JP2024523839A (ja) 2021-06-08 2022-06-08 突然変異体brafを分解する療法薬

Country Status (12)

Country Link
US (2) US20240199581A1 (cg-RX-API-DMAC7.html)
EP (1) EP4351583A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024523839A (cg-RX-API-DMAC7.html)
KR (1) KR20240018446A (cg-RX-API-DMAC7.html)
CN (1) CN117940133A (cg-RX-API-DMAC7.html)
AR (1) AR126108A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022290851A1 (cg-RX-API-DMAC7.html)
CA (1) CA3174245A1 (cg-RX-API-DMAC7.html)
IL (1) IL308748A (cg-RX-API-DMAC7.html)
MX (1) MX2023014059A (cg-RX-API-DMAC7.html)
TW (1) TW202313628A (cg-RX-API-DMAC7.html)
WO (1) WO2022261250A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
SI4073065T1 (sl) 2019-12-10 2025-06-30 F. Hoffmann-La Roche Ag Novi derivati metilkinazolinona
WO2022047145A1 (en) 2020-08-28 2022-03-03 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
WO2022129259A1 (en) 2020-12-18 2022-06-23 F. Hoffmann-La Roche Ag New quinazolinone derivatives
WO2023183470A1 (en) * 2022-03-24 2023-09-28 Vibliome Therapeutics, Llc Modulators of protein kinases
EP4584258A1 (en) * 2022-09-07 2025-07-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
CN118126051A (zh) * 2022-12-02 2024-06-04 C4医药公司 突变体braf降解剂的多晶型物及其制备方法
WO2024201460A1 (en) * 2023-03-30 2024-10-03 Adama Agan Ltd. Process for the preparation of sulfamide derivatives
CN122206684A (zh) 2023-06-30 2026-06-12 默克专利有限公司 用于kras蛋白降解的异双功能化合物
JP2026524477A (ja) 2023-06-30 2026-07-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Krasの分解のためのヘテロ二官能性化合物
EP4780815A1 (en) 2023-09-20 2026-07-29 Aurigene Oncology Limited Heterocyclic compounds as cbp selective degraders
CN122094959A (zh) * 2023-10-31 2026-05-26 C4医药公司 用于降解突变体braf的化合物
CN121045145A (zh) * 2024-05-31 2025-12-02 深圳市塔吉瑞生物医药有限公司 靶向braf蛋白降解靶向嵌合体类化合物及其组合物及用途
WO2026136866A1 (en) 2024-12-20 2026-06-25 Prelude Therapeutics Incorporated Kat6 targeting compounds
WO2026139448A1 (en) 2024-12-23 2026-07-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein
WO2026156134A1 (en) 2025-01-17 2026-07-23 F. Hoffmann-La Roche Ag Tyk2 degraders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020051564A1 (en) * 2018-09-07 2020-03-12 Arvinas Operations, Inc. Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
ATE219660T1 (de) 1994-09-30 2002-07-15 Inex Pharmaceuticals Corp Mittel zum einbringen polyanionischer materialien in zellen
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US5880137A (en) 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6005102A (en) 1997-10-15 1999-12-21 American Home Products Corporation Aryloxy-alkyl-dialkylamines
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
UA68365C2 (en) 1997-11-06 2004-08-16 Wyeth Corp Peroral contraception by combination of anti-estrogen and progestin
US6583170B1 (en) 1998-05-15 2003-06-24 Wyeth 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
US6306663B1 (en) 1999-02-12 2001-10-23 Proteinex, Inc. Controlling protein levels in eucaryotic organisms
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
CO5271696A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Procedimiento para reducir la morbilidad y el riesgo de mortalidad
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
CO5251465A1 (es) 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
US20020013327A1 (en) 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
US6509332B2 (en) 2000-07-06 2003-01-21 Wyeth Methods of treating excessive intraocular pressure
EP1296674A2 (en) 2000-07-06 2003-04-02 Wyeth Use of substituted indole compounds for increasing nitric oxide synthase activity
AU2001273125A1 (en) 2000-07-06 2002-01-21 American Home Products Corporation Combinations of bisphosphonates, estrogenic agents and optionally estrogens
EP1359940A2 (en) 2000-07-06 2003-11-12 Wyeth Combinations of statins, estrogenic agents and optionally estrogens
JP2004502729A (ja) 2000-07-06 2004-01-29 ワイス Ssriおよびエストロゲン剤の組み合わせ
WO2002003989A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating sphincter incontinence
WO2002003988A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating neuropeptide y-related conditions
AU2001271706A1 (en) 2000-07-06 2002-01-21 American Home Products Corporation Use of substituted indole compounds for treating breast disorders
AR030064A1 (es) 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
AU2001271784A1 (en) 2000-07-06 2002-01-21 Wyeth Therapy for prosthesis-related bone degeneration
EP1177787A3 (en) 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
ATE278421T1 (de) 2000-08-11 2004-10-15 Wyeth Corp Verfahren zur behandlung eines östrogenrezeptor positives karzinoms
EP1192945A3 (en) 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
IL145838A (en) 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
US7745651B2 (en) 2004-06-07 2010-06-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
US7399767B2 (en) 2005-01-21 2008-07-15 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
CA2597724A1 (en) 2005-02-14 2007-08-02 Sirna Therapeutics, Inc. Cationic lipids and formulated molecular compositions containing them
CA2640678C (en) 2006-02-03 2015-03-31 Bionomics Limited Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
EP2049518B1 (en) 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents.
JP5064918B2 (ja) 2007-07-17 2012-10-31 サンデン株式会社 可変容量圧縮機の容量制御システム
CN102713618B (zh) 2009-09-16 2015-07-15 新基阿维罗米克斯研究公司 蛋白激酶复合物和抑制剂
EP3205648A1 (en) 2010-06-10 2017-08-16 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
US10005750B2 (en) 2010-10-06 2018-06-26 J-Pharma Co., Ltd. Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
EP2649099A4 (en) 2010-12-07 2016-10-19 Univ Yale SMALL MOLECULAR HYDROPHOBIC LABELING OF FUSION PROTEINS AND INDUCED REMOVAL FROM THIS
CA2819299A1 (en) 2010-12-24 2012-06-28 Merck Sharp & Dohme B.V. N-substituted azetidine derivatives
WO2012118492A1 (en) 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
EP2791132A4 (en) 2011-12-14 2015-08-05 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
BR112014014767A2 (pt) 2011-12-16 2017-06-13 Olema Pharmaceuticals Inc novos compostos de benzopirano, composições e usos dos mesmos
KR102438072B1 (ko) 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
CN104145514B (zh) 2012-08-01 2018-03-13 华为技术有限公司 用于同步的方法、装置及系统
WO2014160200A1 (en) 2013-03-13 2014-10-02 Dana-Farber Cancer Institute, Inc. Ras inhibitors and uses thereof
AP2015008858A0 (en) 2013-05-28 2015-11-30 Astrazeneca Ab Chemical compounds
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
EA031077B1 (ru) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
BR112015030595A2 (pt) 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
SG11201607334YA (en) 2014-03-13 2016-10-28 Hoffmann La Roche Therapeutic combinations with estrogen receptor modulators
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
EP4649963A3 (en) 2014-04-14 2026-05-13 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
US10745360B2 (en) 2014-07-16 2020-08-18 Development Center For Biotechnology Quinoxaline compounds, method for preparing the same and use thereof
US20160022642A1 (en) 2014-07-25 2016-01-28 Yale University Compounds Useful for Promoting Protein Degradation and Methods Using Same
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
WO2016065139A1 (en) 2014-10-24 2016-04-28 Fl Therapeutics Llc 3-substituted piperidine-2, 6-diones and non-covalent complexes with albumin
TWI784255B (zh) 2014-12-18 2022-11-21 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
JP6815318B2 (ja) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
AU2016232705C1 (en) 2015-03-18 2021-06-17 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
CA2988414C (en) 2015-06-04 2023-09-26 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2017024317A2 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
BR112018008918A8 (pt) 2015-11-02 2019-02-26 Univ Yale compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
CN109153644B (zh) 2016-03-16 2022-10-21 H·李·莫菲特癌症中心研究有限公司 用以增强效应t细胞功能的针对cereblon的小分子
WO2017197046A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN121974842A (zh) 2016-05-10 2026-05-05 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
WO2017201069A1 (en) 2016-05-18 2017-11-23 Biotheryx, Inc. Oxoindoline derivatives as protein function modulators
JP2020504711A (ja) 2016-12-21 2020-02-13 バイオセリックス, インコーポレイテッド タンパク質を標的とすることにおいて使用するための、チエノピロール誘導体、その組成物、方法、および使用
IL325835A (en) 2016-12-23 2026-03-01 Univ Yale Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
IL319363A (en) 2017-01-31 2025-05-01 Arvinas Operations Inc Cervalon ligands and bifunctional compounds containing them
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
MX2020003190A (es) 2017-09-22 2020-11-11 Kymera Therapeutics Inc Degradadores de proteinas y usos de los mismos.
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
JP2021512153A (ja) * 2018-01-26 2021-05-13 イエール ユニバーシティ タンパク質分解のイミド系モジュレーターおよび使用方法
CA3095912A1 (en) 2018-04-13 2019-10-17 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
WO2020142612A1 (en) 2019-01-03 2020-07-09 Genentech, Inc. Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases.
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療braf相關的疾病和失調症之化合物
SI4073065T1 (sl) 2019-12-10 2025-06-30 F. Hoffmann-La Roche Ag Novi derivati metilkinazolinona
CA3158541A1 (en) 2019-12-10 2021-06-17 Cosimo Dolente New braf inhibitors as paradox breakers
MX2022015703A (es) 2020-06-09 2023-01-24 Array Biopharma Inc Compuestos para el tratamiento de enfermedades y trastornos asociados a braf.
WO2022047145A1 (en) 2020-08-28 2022-03-03 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
CN118561841A (zh) 2020-12-18 2024-08-30 豪夫迈·罗氏有限公司 新的芳基-吡啶并-嘧啶-酮衍生物
WO2022129259A1 (en) 2020-12-18 2022-06-23 F. Hoffmann-La Roche Ag New quinazolinone derivatives
IL308015A (en) 2021-06-09 2023-12-01 Hoffmann La Roche Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
JP2024522603A (ja) 2021-06-09 2024-06-21 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト (3r)-n-[2-シアノ-4-フルオロ-3-(3-メチル-4-オキソ-キナゾリン-6-イル)オキシ-フェニル]-3-フルオロ-ピロリジン-1-スルホンアミドの新規固形物
CN117642166A (zh) 2021-06-09 2024-03-01 中外制药株式会社 用于癌症治疗的组合疗法
IL312171A (en) 2021-11-04 2024-06-01 Hoffmann La Roche Innovative use of the quinazolinone compound for cancer treatment
KR20240115893A (ko) 2021-12-08 2024-07-26 어레이 바이오파마 인크. N-(2-클로로-3-((5-클로로-3-메틸-4-옥소-3,4-다이하이드로퀴나졸린-6-일)아미노)-4-플루오로페닐)-3-플루오로아제티딘-1-설폰아미드의결정질 형태

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020051564A1 (en) * 2018-09-07 2020-03-12 Arvinas Operations, Inc. Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides

Also Published As

Publication number Publication date
WO2022261250A1 (en) 2022-12-15
AR126108A1 (es) 2023-09-13
IL308748A (en) 2024-01-01
WO2022261250A8 (en) 2023-02-23
TW202313628A (zh) 2023-04-01
MX2023014059A (es) 2024-03-12
US20240199581A1 (en) 2024-06-20
EP4351583A4 (en) 2025-06-04
KR20240018446A (ko) 2024-02-13
CN117940133A (zh) 2024-04-26
US12486253B2 (en) 2025-12-02
US20250115580A1 (en) 2025-04-10
EP4351583A1 (en) 2024-04-17
CA3174245A1 (en) 2022-12-15
AU2022290851A1 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
US12486253B2 (en) Therapeutics for the degradation of mutant BRAF
US12486290B2 (en) Isoindolinone and indazole compounds for the degradation of EGFR
US12157735B2 (en) Compounds for targeted degradation of BRD9
US20230233692A1 (en) Compounds for targeted degradation of ret
US20240158418A1 (en) EGFR Degraders to Treat Cancer Metastasis to the Brain or CNS
AU2024374279A1 (en) Compounds for the degradation of mutant braf
HK40131457A (en) Isoindolinone and indazole compounds for the degradation of egfr
EA052899B1 (ru) Изоиндолиноновые и индазольные соединения для деструкции рецептора эпидермального фактора роста (egfr)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250604

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250604

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260630